Trial Progress: Social media chatter has centered on Sellas Life Sciences Group's REGAL Phase 3 trial reaching 78 out of 80 events, with the independent data monitoring committee recommending continuation without changes. Observers note the company's clean balance sheet and absence of near-term financing needs as factors supporting ongoing momentum ahead of data readout.
Short Interest Dynamics: Discussions highlight declining short exposure in the stock amid anticipation of pivotal results, with some participants suggesting this setup could amplify moves if outcomes exceed expectations. Analysts in the conversation emphasize that positive surprises from the AML pipeline remain the key driver in the near term.
Executive Visibility: Recent comments point to heightened CEO engagement, including upcoming media appearances, as the team advances toward database lock and regulatory preparations. This development has kept the focus on execution risks and rewards tied to the upcoming clinical milestones.
Note: This discussion summary was generated from an AI condensation of post data.
Sellas Life Sciences Group Hedge Fund Activity
We have seen 106 institutional investors add shares of Sellas Life Sciences Group stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 6,208,185 shares (+283.7%) to their portfolio in Q1 2026, for an estimated $26,260,622
- BLACKROCK, INC. added 4,657,356 shares (+61.8%) to their portfolio in Q1 2026, for an estimated $19,700,615
- JONES FINANCIAL COMPANIES LLLP added 1,245,834 shares (+290.2%) to their portfolio in Q1 2026, for an estimated $5,269,877
- MILLENNIUM MANAGEMENT LLC removed 1,228,325 shares (-88.5%) from their portfolio in Q1 2026, for an estimated $5,195,814
- GEODE CAPITAL MANAGEMENT, LLC added 835,269 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $3,533,187
- UBS GROUP AG added 696,692 shares (+1429.8%) to their portfolio in Q1 2026, for an estimated $2,947,007
- MARSHALL WACE, LLP added 696,494 shares (+52.0%) to their portfolio in Q1 2026, for an estimated $2,946,169
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
